Boekhorst Paul Francis Olivier te
Known title: President and CEOCIK: 0002095704
Boekhorst Paul Francis Olivier te's purchase track record
Boekhorst Paul Francis Olivier te has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/18/2026 | ICCC | $76K | +5.2% | pending | — |
| 12/2/2025 | ICCC | $49K | +28.0% | +95.8% | +11.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ICCC | ▲ Buy | Open Market | 8,000 | $76K | 6/18/2026 | View on chart |
| ICCC | ▲ Buy | Open Market | 3,521 | $18K | 12/3/2025 | View on chart |
| ICCC | ▲ Buy | Open Market | 2,556 | $13K | 12/3/2025 | View on chart |
| ICCC | ▲ Buy | Open Market | 3,708 | $18K | 12/2/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
ICCC featured in research roundup alongside major tech and pharma names
ImmuCell Corporation was included in a recent Yahoo Finance article highlighting top research reports for Alphabet, Mastercard, and AbbVie. This mention places ICCC in the same discussion as large-cap companies, though the specific details of the research for ICCC are not provided in the summary. The stock currently trades within its 52-week range, with a trailing P/E of 115.1.
ICCC featured in research roundup alongside major tech and pharma names. ImmuCell Corporation was included in a recent Yahoo Finance article highlighting top research reports for Alphabet, Mastercard, and AbbVie. This mention places ICCC in the same discussion as large-cap companies, though the specific details of the research for ICCC are not provided in the summary. The stock currently trades within its 52-week range, with a trailing P/E of 115.1.